WHC is still in active development. Read this to understand our approach.
depiction of DYDCUQKUCUHJBH-UHFFFAOYSA-N.svg
isomerdesign

D-Cycloserine

Check on isomerdesign

pubchem

Cycloserine

Check on pubchem

drugmap

Cycloserine

Check on drugmap

Data

InChI: InChI=1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)

Synonyms: CYCLOSERINE (D),NSC756712,NSC 154851,SR-01000075432-9,CHEMBL771,Cycloserinum,CYCLOSERINE [WHO-IP],BIDD:GT0707,SBI-0050240.P004,SR-01000075432-5,SMP1_000167,Tebemicina,SPBio_000008,D-4-Amino-3-isossazolidone,SR-01000075432-10,Pharmakon1600-01500215,F2173-1228,SC-49088, Micoserina,NSC-154851,BPBio1_001252,3-Isoxazolidinone, 4-amino-, (R),IDI1_000098,Cycloserine, Pharmaceutical Secondary Standard; Certified Reference Material, (4R)-4-aminoisoxazolidin-3-one,SCHEMBL34322, Wasserina,NCGC00016306-07,Cycloserin, Seromycin, (+)-4-Amino-3-isoxazolidinone,NCGC00015213-02,KBio3_001341,NSC-76029,3-Isoxazolidinone, 4-amino-, d-,68-41-7,SPECTRUM1500215, Seromycin (TN),D-Cycloserine, >=96.0% (NT),MFCD00005353,D00877,4-Isoxazolidinamine, 3-oxo-, (D)-, PA 94,(R)-4-AMINO-ISOXAZOLIDIN-3-ONE,Spectrum5_000797,(R)-(+)-Cycloserine,SR-01000759389,ZINC34676245,Prestwick0_001089,(4R)-4-aminoisoxazolidin-3-one,DB00260,NCGC00015213-01,CCG-39705,Cicloserina,CYCLOSERINE [WHO-DD],NC00050, Cycloserin,Oxamycin,DTXSID8022870,(R)-4-AMINOISOXAZOLIDIN-3-ONE,ACT04767,SR-01000075432-2,D-Cycloserine, powder, Closina, C-9400, D-4-Amino-3-isossazolidone [Italian],CYCLOSERINE [JAN],NINDS_000098,Tox21_500252,C 3909,Prestwick3_001089,NCGC00016306-01,Prestwick2_001089,3-Isoxazolidinone, 4-amino-, (4R)-,.alpha.-Cycloserine, R(+)-4-Amino-3-isoxazolidinone,Cycloserine, D(+),CYCLOSERINE [USP MONOGRAPH], Oxamycin, Oxamicina [Italian],AKOS015994626, alpha-Cycloserine,D-Cycloserine synth. BP 88,Lopac-C-1159,HSDB 3218,cycloserine-(d), Alpha-Cycloserine,Cyclorin, (R)-4-Amino-Isoxazolidin-3-One,D-amino-3-isoxazolidinone,s1998,Tox21_110361_1,KBioGR_000890, Cicloserina [INN-Spanish],RO-1-9213,NCGC00093713-01, D-4-amino-3-isoxazolidinone,D-4-amino-3-isoxazolidone, FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09,D-4-Amino-3-isossazolidone [Italian],R-(+)-Cycloserine,Tisomycin,Farmiserina, orientomycin,Novoserin,HMS2098I20, C-9390,HMS3260D06, cycloserine,MLS000758215,Cycloserine, United States Pharmacopeia (USP) Reference Standard, (R)-4-Amino-3-isoxazolidone,Cycloserinum [INN-Latin],DCS, Novoserin,UNII-95IK5KI84Z,AI3-50153,Wasserina, (R)-(+)-Cycloserine, Oxamicina, R-4-Amino-3-isoxazolidinone,SPBio_003029,C08057,CYCLOSERINE [HSDB], 68-41-7, I-1431,Closina,HMS2232F03,NCGC00016306-03,D-Cycloserine, synthetic,NSC-756712,EU-0100252,CYCLOSERINE [VANDF], D-CS,(+)-Cycloserine, R-(+)-Cycloserine,SR-01000759389-4,PA-94,CHEBI:40009,NCGC00016306-02,SR-01000075432-1,NJ-21,Prestwick1_001089,3-Isoxazolidinone, 4-amino-, (4R)- (9CI),BSPBio_001138,D-CS, (R)-Cycloserine,Q418508, PA-94, (+)-Cycloserine,(+)-4-Amino-3-isoxazolidinone,D-(+)-Cycloserine,Spectrum3_000371,(R)-(+)-4-Amino-3-isoxazolidinone,1pb9,EN300-97131, Farmiserina,HMS2051C15,DSSTox_GSID_22870,EINECS 200-688-4,KBio1_000098,D-cycloserine, D-(+)-Cycloserine, DRG-0195,Oxamicina [Italian],NCGC00016306-08,Cyclo-D-serine,Seromycin, Miroseryn, 3-Isoxazolidinone, 4-amino-, D,4-Amino-3-isoxazolidinone, (R)-, Cyclorin,Z1198154206,CAS-339-72-0, (R)-4-Amino-3-isoxazolidinone,AB00443920,NCGC00093713-02,NCGC00016306-04,NC00676,HS-0079,4AX,(R)-Cycloserine,3-Isoxazolidinone, 4-amino-, (R)-,CYCLOSERINE [INN],4-Amino-3-isoxazolidinone, D-,Cycloserine (JP17/USP/INN),(4R)-4-Amino-3-isoxazolidinone,D-Cycloserine,CYCLOSERINE [MART.],D-Oxamicina, (4R)-4-Amino-3-isoxazolidinone,C-9390,BDBM50038178, Miroserina,(4R)-4-azaniumyl-4,5-dihydroisoxazol-3-olate;(R)-4-AMINOISOXAZOLIDIN-3-ONE,Tox21_110361, E-733-A, 3-Isoxazolidinone, 4-amino-, (4R)-(9CI),DSSTox_CID_2870,Seromycin (TN),MLS002548887,NCGC00260937-01, Cycloserinum,AB00443920_09, D-Oxamycin,Micoserina,I-1431,005C353,CYCLOSERINE [MI],NCGC00015213-03,Oxamicina,NCGC00016306-05,Cicloserina [INN-Spanish],3-Isoxazolidinone, 4-amino-, D,Miroseryn,Cycloserine, D-,KBioSS_001340,Serine, cyclo-,AB00443920_10,K-300, Closerin,DivK1c_000098,FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09,R(+)-4-Amino-3-isoxazolidinone,HMS3715I14,Spectrum4_000305,KBio2_001340,CYCLOSERINE [ORANGE BOOK], Cicloserina,(R)-4-Amino-3-isoxazolidinone,HMS1920C06,C-9400,Cicloserina [Italian],D-4-amino-3-isoxazolidinone, Cycloserine (JP15/USP/INN),(4R)-4-amino-1,2-oxazolidin-3-one,LMPK14000007, RO-1-9213,MLS001423962, K-300,Lopac0_000252,Lopac-C-7005,SR-01000075432, D-4-Amino-3-isossazolidone,(R)-4-Amino-3-isoxazolidone,SMR000058313, Cicloserina,alpha-Cycloserine,CYCLOSERINE [USP IMPURITY],D-Oxamycin,orientomycin,Closerin,KBio2_006476,Spectrum_000860, (R)-(+)-4-Amino-3-isoxazolidinone, (R)-4-AMINO-ISOXAZOLIDIN-3-ONE,BRN 0080798, Tisomycin,95IK5KI84Z,PA 94,HMS2091I14,AC-4721,NCGC00016306-17,cycloserine,4-27-00-05549 (Beilstein Handbook Reference),HMS500E20,HMS3259L19,(R)-3-Isoxazolidinone, 4-amino-,Lopac-C-3909, Cicloserina [Italian], Cyclo-D-serine, 3-Isoxazolidinone, 4-amino-, (R), Orientomycin,SDCCGSBI-0050240.P005,GTPL9489, SC-49088,A836140,DSSTox_RID_76766, 3-Isoxazolidinone, 4-amino-, (+)-(8CI),BSPBio_002121, Tebemicina, (4R)-4-amino-1,2-oxazolidin-3-one,Cycloserine [USP:INN:BAN:JAN], Cycloserinum [INN-Latin],DRG-0195,3-Isoxazolidinone, 4-amino-, (+)-,Spectrum2_000084,KBio2_003908,3-Isoxazolidinone, 4-amino-, (+)- (8CI), C 3909,CYCLOSERINUM [WHO-IP LATIN],CAS-68-41-7, D-4-amino-3-isoxazolidone, Cycloserine [INN:BAN:JAN], (R)-4-AMINOISOXAZOLIDIN-3-ONE,E-733-A,BDBM50103516, D-amino-3-isoxazolidinone,HMS1571I20,LP00252,Miroserina,HY-B0030

Estimated data

Solubility: 0.09 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 55.3% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.